XOMA Corporation New CEO Says Company Expects to Initiate Global Gevokizumab Phase 3 Program in Q2 of 2012

XOMA Corporation XOMA new CEO highlighted the company's future plans: "We have multiple goals to achieve in 2012. Of greatest near-term importance, we anticipate initiating our global gevokizumab Phase 3 program in non-infectious uveitis, including Behçet's uveitis, in the second quarter of 2012. We expect to complete our Phase 2 proof-of-concept trial of gevokizumab in moderate to severe acne as part of our plan to pinpoint additional indications that can expand the commercial opportunities for our lead drug candidate. This program will be expanded in 2012 when we launch two additional proof-of-concept studies for gevokizumab. These goals are aligned fully with our strategy to maximize the potential of XOMA's flagship product, pursue discovery-based opportunities, and establish XOMA as a U.S. commercial presence."